If you're an adult with extra weight but don't have diabetes, taking a weekly 2.4 mg shot of semaglutide for about a year and a half can help you lose around 13 kg of fat, including some deep belly fat, while mostly keeping your muscle — even though you might lose a little muscle too, the fat loss is much bigger.
See the scientific wording
In non-diabetic adults with overweight or obesity, administration of once-weekly semaglutide at a dose of 2.4 mg over 68 weeks results in a mean reduction of fat mass by 13.2 kg and visceral fat by 0.25 kg, with a relative increase in lean body mass proportion despite an absolute decrease, indicating a preferential loss of fat over lean tissue.
Contradicted by evidence
Randomized trialsOne high-quality study contradicts this claim.
What the research says
1 study reviewedSupporting (0)
No supporting studies found yet
We'll keep looking as more research is published.
Contradicting (1)
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Randomized Controlled TrialHuman2021
The study tested the same drug and found big weight loss, but it didn’t measure how much was fat or muscle, so we can’t say if the specific numbers in the claim are right.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 contradicting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
If you're an adult with extra weight but don't have diabetes, taking a weekly 2.4 mg shot of semaglutide for about a year and a half can help you lose around 13 kg of fat, including some deep belly fat, while mostly keeping your muscle — even though you might lose a little muscle too, the fat loss is much bigger.
Evidence from Studies
Supporting (0)
Community contributions welcome
Contradicting (1)
Community contributions welcome
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
The study tested the same drug and found big weight loss, but it didn’t measure how much was fat or muscle, so we can’t say if the specific numbers in the claim are right.
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Randomized Controlled Trials on Once-Weekly Semaglutide 2.4 mg for Fat Mass and Visceral Fat Reduction in Non-Diabetic Adults with Overweight or Obesity
Comprehensive synthesis of double-blind, placebo-controlled RCTs evaluating semaglutide 2.4 mg weekly for at least 68 weeks, measuring changes in fat mass, visceral fat, and lean body mass in non-diabetic adults with BMI ≥25.
Double-Blind, Placebo-Controlled Trial of Semaglutide 2.4 mg Weekly on Body Composition in Non-Diabetic Adults with Overweight or Obesity Over 68 Weeks
Randomized, double-blind, placebo-controlled trial with DEXA or MRI-based body composition tracking over 68 weeks in non-diabetic adults (BMI ≥25), comparing semaglutide 2.4 mg weekly vs. placebo.
Prospective Cohort Study of Real-World Semaglutide Use and Body Composition Changes in Non-Diabetic Adults with Overweight or Obesity
Longitudinal follow-up of non-diabetic adults prescribed semaglutide 2.4 mg weekly for weight management, with serial body composition measurements over 68 weeks compared to matched controls not receiving GLP-1 agonists.
Case-Control Study Comparing Body Composition Outcomes in Semaglutide Users vs. Non-Users Among Non-Diabetic Adults with Obesity
Matched case-control study identifying individuals with similar baseline characteristics, comparing those treated with semaglutide 2.4 mg weekly for ≥68 weeks to untreated controls, assessing body composition outcomes.
Cross-Sectional Analysis of Body Composition in Non-Diabetic Adults on Long-Term Semaglutide Therapy
Single-time assessment of fat mass, visceral fat, and lean mass in non-diabetic adults with overweight or obesity currently on semaglutide 2.4 mg weekly for approximately 68 weeks, compared to non-users.